TROP2-Targeting Therapies in NSCLC: What You Need to Know

TROP2-Targeting Therapies in NSCLC: What You Need to Know

Med-IQ Select
Online Course | Specialties: Oncology
Released: 9/10/2020
Expires: 9/9/2021
Max Credits: 0.5
Jump to Education

Edward Garon, MD
Director, Thoracic Oncology Program
Associate Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Baltimore, MD

Jane Frutchey, MS
Managing Editor
Baltimore, MD

Rebecca L. Julian, MS, ELS
Senior Manager, Editorial
Baltimore, MD

Samantha Gordon
Accreditation Manager
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD 

Haifa Kassis, MD
West Roxbury, MA 
Learning Objectives
Upon completion, participants should be able to:

  • Explain the role of TROP2 in oncogenesis and the novel agents targeting this glycoprotein in NSCLC
  • Translate emerging clinical efficacy and safety findings with TROP2 inhibitors, including the identification of patients who might benefit from these therapies 

Target Audience
This activity is intended for oncologists.
Statement of Need
Despite the progress made in NSCLC treatment, patients eventually experience disease progression, underscoring the urgent need for additional treatment options that help extend survival. TROP2 antibody drug-conjugates (ADCs) are in clinical development for pretreated patients with NSCLC and are demonstrating promising activity. TROP2 ADCs are adding to the volume of new data that oncologists must interpret and synthesize. Therefore, oncologists require education on these emerging therapeutic agents to understand the data and appropriately select patients who are most likely to benefit from them.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Medium/Method of Participation
This is a 0.5-credit CME activity. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: September 10, 2020
Expiration Date: September 9, 2021
Estimated Time to Complete This Activity: 30 minutes

Drug/Product Usage by Faculty
Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Edward Garon, MD
Consulting fees/advisory boards: GlaxoSmithKline, Novartis Pharmaceuticals Corporation
Contracted research: AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Inc., Genentech, Iovance Biotherapeutics, Merck & Co, Inc., Mirati Therapeutics, Neon Pharmaceuticals, Novartis Pharmaceuticals Corporation   
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity. 
Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit:

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
© 2020 Med-IQ, Inc.


Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • TROP2 is a glycoprotein that is upregulated in NSCLC; it is associated with poor survival rates
  • ADCs that target TROP2 and deliver a toxic payload into lung cancer cells are in clinical trials in heavily pretreated patients with NSCLC
  • Data on the safety and efficacy of TROP2-targeted ADC agents sacituzumab govitecan and DS-1062 (investigational drug) in refractory advanced or metastatic NSCLC are emerging from early phase clinical trials
  • Data suggest that TROP2-targeted agents can be effective in patients whose tumors did not respond to or progressed after multiple treatments, including prior ICI therapy

View reference list.

Click “Continue” at the bottom of this screen to answer any pre-activity questions and proceed to the activity, or select a specific module in the menu to the left. To receive credit and a certificate, you must complete all of the modules in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.